Jpmorgan Chase & CO Instil Bio, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.4 - $0.63 $8,080 - $12,726	20,201 Added 417.29%	25,042 $10,000
Q2 2023 Aug 11, 2023	SELL	$0.51 - $0.67 $256,977 - $337,597	-503,877 Reduced 99.05%	4,841 $2,000
Q1 2023 May 18, 2023	BUY	$0.6 - $0.91 $31,984 - $48,509	53,307 Added 11.71%	508,718 $335,000
Q1 2023 May 11, 2023	SELL	$0.6 - $0.91 $23,331 - $35,386	-38,886 Reduced 7.87%	455,411 $300,000
Q4 2022 Feb 13, 2023	SELL	$0.48 - $5.33 $1,747 - $19,406	-3,641 Reduced 0.73%	494,297 $312,000
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $843,328 - $1.34 Million	181,361 Added 57.29%	497,938 $2.41 Million
Q2 2022 Aug 11, 2022	SELL	$4.21 - $11.15 $10,651 - $28,209	-2,530 Reduced 0.79%	316,577 $1.46 Million
Q1 2022 May 11, 2022	BUY	$8.48 - $18.1 $1.66 Million - $3.54 Million	195,687 Added 158.55%	319,107 $3.43 Million
Q4 2021 Feb 10, 2022	BUY	$15.37 - $22.5 $1.74 Million - $2.54 Million	112,947 Added 1078.46%	123,420 $2.11 Million
Q3 2021 Nov 12, 2021	BUY	$15.05 - $23.28 $157,618 - $243,811	10,473 New	10,473 $186,000

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $2.67B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.